The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
BI-EASE DUO ALLERGY (Teva Pharma Australia Pty Ltd)
Product name
BI-EASE DUO ALLERGY
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
128 (255 working days)
Active ingredients
azelastine hydrochloride, fluticasone propionate
Registration type
New generic medicine
Indication
Symptomatic treatment of moderate to severe allergic rhinitis for up to 6 months